Role of Guduchi Ksheer Taila and Tila Taila Matra Basti in Reducing Uric Acid in Gout Patients A Clinical Study

A COMPARATIVE OPEN LABELLED STUDY OF GUDUCHI KSHEER TAIL AND TIL TAILMATRA BASTI IN THE MANAGEMENT OF VATARAKTA WITH SPECIAL REFERENCE TO GOUT - NIL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/066557

Enrollment

Registered

2024-04-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M109- Gout, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients presenting features as Vatarakta as per text 2) Irrespective of sex. 3) Willing to participate.

Exclusion criteria

Exclusion criteria: 1) Pregnancy and Lactation 2) patients of severe anorectal disorders 3) Major systemic diseases. 4) All arthritic conditions other than Vatarakta 5) chronic renal disorders.

Design outcomes

Primary

Measure	Time frame
The primary outcome measure will be rated using the Assessment criteria A) Subjective (Day 0, Day 16, Day30) Visual analogue scale (1to 10) Presentation at affected joints 1. Swelling (Shotha) 2. Pain (Pida, Daha,Toda) 3. Stiffness (Kathinya) 4. Tenderness (Sparshasahatva) 5. Functional score (Ability to perform joint functions) Objective Criteria Following objective criteria will be assessed on day 0, day16, day30 Lab investigation a. Serum uric acid level b. Erythrocyte Sedimentation Rate (By Win Trobe Method) c. Complete Blood Count Health assessment questionnaire disability index (H A Q DITimepoint: The primary outcome measure will be rated using the Assessment criteria A) Subjective (Day 0, Day 16, Day30) Visual analogue scale (1to 10) Presentation at affected joints 1. Swelling (Shotha) 2. Pain (Pida, Daha,Toda) 3. Stiffness (Kathinya) 4. Tenderness (Sparshasahatva) 5. Functional score (Ability to perform joint functions) Objective Criteria Following objective criteria will be assessed on day 0, day16, day30 Lab investigation a. Serum uric acid level b. Erythrocyte Sedimentation Rate (By Win Trobe Method) c. Complete Blood Count Health assessment questionnaire disability index (H A Q DI	—

Measure

Time frame

The primary outcome measure will be rated using the Assessment criteria A) Subjective (Day 0, Day 16, Day30) Visual analogue scale (1to 10) Presentation at affected joints 1. Swelling (Shotha) 2. Pain (Pida, Daha,Toda) 3. Stiffness (Kathinya) 4. Tenderness (Sparshasahatva) 5. Functional score (Ability to perform joint functions) Objective Criteria Following objective criteria will be assessed on day 0, day16, day30 Lab investigation a. Serum uric acid level b. Erythrocyte Sedimentation Rate (By Win Trobe Method) c. Complete Blood Count Health assessment questionnaire disability index (H A Q DITimepoint: The primary outcome measure will be rated using the Assessment criteria A) Subjective (Day 0, Day 16, Day30) Visual analogue scale (1to 10) Presentation at affected joints 1. Swelling (Shotha) 2. Pain (Pida, Daha,Toda) 3. Stiffness (Kathinya) 4. Tenderness (Sparshasahatva) 5. Functional score (Ability to perform joint functions) Objective Criteria Following objective criteria will be assessed on day 0, day16, day30 Lab investigation a. Serum uric acid level b. Erythrocyte Sedimentation Rate (By Win Trobe Method) c. Complete Blood Count Health assessment questionnaire disability index (H A Q DI

—

Secondary

Measure	Time frame
secondary outcomes were health assestment questionnarire disability index subscale (pain , Stiffness etc )also safety ( adverse events and serious adverse events ) are assessed.Timepoint: secondary outcomes will be assedssed at base line,0 , 16 and 30 day	—

Countries

India

Contacts

Public ContactDr Subodh Chandrakant Patil

A P M s Ayurved College Sion Mumbai

drpankajtathed@gmail.com8928783687

Outcome results